Bionano Genomics, Inc. (NASDAQ:BNGO) Q4 2025 Earnings Call Transcript March 23, 2026 Bionano Genomics, Inc. reports earnings ...

Attributed Q4 revenue declines to supply constraints from a manufacturing partner for silicon wafers, creating a backlog of ...

Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 demonstrated the ...

The market misinterprets past COVID-era revenue growth for 10x Genomics and fails to integrate current sector growth. Read ...

Bionano Genomics Inc (BNGO) reports improved gross margins and cost management amid revenue declines, with promising growth ...

A free open-access webinar will introduce the Cancer Genome Interpreter (CGI), an advanced bioinformatics tool to interpret mutations in cancer genomes developed by IRB Barcelona and co-created with ...

Te Whatu Ora starts genomics testing pilot. Te Whatu Ora Health New Zealand has launched a two-year pilot to deliver local ...

Good day, and welcome to the Bionano Fourth Quarter and Full Year 2025 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Webb ...

OGM VIA customers represent a meaningful software revenue stream and a natural on-ramp to broader Bionano Genomics, Inc.

Bionano Genomics BNGO just pulled back the curtain on its fourth-quarter results, and the message is clear: the company is ...

Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 demonstrated the momentum we built as a business,” commented ...

Fauna Bio, a biotechnology company pioneering the use of extreme mammal biology and comparative genomics to discover novel therapeutic targets, today announced the designation of a target under its ...